MedTrace Logo

Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)

NCT02661009 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2016-01-21

No results posted yet for this study

Summary

In this clinical trial, investigators select FFPE and plasma samples of non-small cell lung cancer which are used for quantitative detection of four kinds of EGFR(Epidermal Growth Factor Receptor) mutations. By the following two aspects, investigators evaluate the clinical performance of the EGFR quantitative kits.

1. methodology validation: To certify the equivalence between the EGFR quantitative kit and the common used detection methods.
2. analysis of the relationship between the type and proportion of EGFR sensitive mutation and EGFR-TKI benefit.

Conditions

  • Non Small Cell Lung Cancer
  • EGFR-TKI Resistant Mutation
  • EGFR-TKI Sensitizing Mutation

Sponsors & Collaborators

  • Shanghai Pulmonary Hospital, Shanghai, China

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Shanghai Chest Hospital

    collaborator OTHER

  • GenoSaber

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02661009 on ClinicalTrials.gov